SCHEMBL4476585

SCHEMBL4476585

O=c1c(Br)c(NS(=O)(=O)Cc2ccccc2)ccn1Cc1cccc(F)c1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.51
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KMT2A Q03164 2/20 0.42
BRD4 O60885 1/20 0.42
POLB P06746 1/20 0.42
THRB P10828 1/20 0.42
PARP14 Q460N5 1/20 0.41
MEN1 O00255 1/20 0.39
PKM P14618 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EPHX2 P34913 1/20 0.39
PPARG P37231 1/20 0.39
PTGER3 P43115 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4468484 0.87 MAPK14 (0.51) MAPK14ALDH1A1KDM4EL3MBTL1KMT2A
SCHEMBL4478413 0.83 MAPK14 (0.56) MAPK14ALDH1A1KDM4EL3MBTL1KMT2A
SCHEMBL4389631 0.82 ALDH1A1 (0.55) MAPK14ALDH1A1KDM4EL3MBTL1KMT2A
SCHEMBL3521808 0.81 MAPK14 (0.44) MAPK14ALDH1A1KDM4EL3MBTL1KMT2A
SCHEMBL4474073 0.79 MAPK14 (0.57) MAPK14ALDH1A1KDM4EL3MBTL1KMT2A
SCHEMBL4466743 0.77 MAPK14 (0.60) MAPK14ALDH1A1KDM4EL3MBTL1KMT2A
SCHEMBL4378463 0.76 MAPK14 (0.64) MAPK14ALDH1A1KDM4EL3MBTL1KMT2A
SCHEMBL14547795 0.76 MAPK14 (0.58) MAPK14ALDH1A1KDM4EL3MBTL1KMT2A
SCHEMBL4382222 0.75 MAPK14 (0.57) MAPK14ALDH1A1KDM4EL3MBTL1KMT2A
SCHEMBL4476692 0.74 MAPK14 (0.54) MAPK14ALDH1A1KDM4EL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US claimed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MAPK14 41/4885ALDH1A1 787/4885KDM4E 3869/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPK14 53/4885ALDH1A1 741/4885KDM4E 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.